CORDIS
EU research results

CORDIS

English EN

Holistic Quantum Mechanics Based Platform to Accelerate Drug Discovery

Project information

Grant agreement ID: 953418

Status

Grant agreement signed

  • Start date

    1 September 2020

  • End date

    31 August 2022

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 1 369 575

  • EU contribution

    € 958 702,50

Coordinated by:

PHARMACELERA SL

Spain

Objective

Drug discovery & development projects are long processes that take approximately 15 years from the moment a molecular
target is discovered to its market launch. During the past two decades, the costs of new drug development has increased
from €1 billion in 2000 to €2.58 billion in 2015.
The increase is due in part to the difficulty to find New Molecular Entities (NME) subject to be patented. Computer-aided
drug design (CADD) tools are used to perform virtual screening, design and the optimization of candidate molecules, but
they focus in single aspects of the molecule (e.g. activity or toxicity) giving a narrow view at each development stage of the
early drug discovery process, translating into expensive design cycles. The chemical space is very large and simple
therapeutic areas have already been explored, therefore, the quality of the data obtained with CADD solutions is low. Only
4% of NMEs will successfully make it from the initial discovery phase to launch.
To solve this problem, Pharamacelera has developed PharmScreen2, a unique and propiesoftware for drug discovery using novel
molecular descriptors that enables accurate predictions of molecular properties of candidate molecules, which thereby
increases the success rate of leads identification by 3x and will reduce the overall costs of drug design & development
processes by 25%. PharmScreen2 is the only software that integrates the capability of performing advanced simulations of
all the properties that are key in later drug discovery stages, such as activity, absorption, distribution, metabolism, toxicity
(ADME-Tox) giving a holistic view. PharmScreen2 can analyse behaviors of new candidate molecules, predict the
compounds’ performance in later stages and identify undesired effects early.
The main objective of this project is to finalise the development of PharmScreen2, PoC with industrial partners and prepare the
new PharmScreen2 from market. Pharmacelera estimates a total market size of 5.3 billion by 2023.

Coordinator

PHARMACELERA SL

Address

Cl Esteve Pila Num, 11 P.1 Pta.1
08173 Saint Cugat Del Valles Barcelona

Spain

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 958 702,50

Project information

Grant agreement ID: 953418

Status

Grant agreement signed

  • Start date

    1 September 2020

  • End date

    31 August 2022

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 1 369 575

  • EU contribution

    € 958 702,50

Coordinated by:

PHARMACELERA SL

Spain